Highest-materiality recent filing
Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.
Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026
Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.
Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026
Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).
Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share
Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.
Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.
Candel Therapeutics hosts virtual R&D Day with pipeline overview
Virtual R&D Day held December 5, 2025, from 11:00 am to 1:45 pm ET.
Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital
Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.
Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data
Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.
Candel Therapeutics extends office lease through August 2029
Lease term extended from August 31, 2026 to August 31, 2029 for 15,197 sq ft in Needham, MA.
Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.
Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67
Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.
Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025
Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.
Candel shareholders elect three Class I directors, ratify KPMG as auditor
Renee Gaeta, Gary J. Nabel, and Joseph C. Papa elected as Class I directors for three-year terms (for/withheld: 13.7M/2.3M, 11.6M/4.4M, 12.8M/3.2M).
Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026
Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.
FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint
RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.
Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.
On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025
On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.
Max materiality 0.85 · Median 0.72 · Most common event other_material